Implants and injectables: PrEP in the future
The ‘long tail’ problem: injected-PrEP trial will be extended due to persistence of drug in companion study
Controlling the HIV epidemic: ambitious funding, expanded workforce, innovations and micro-focus needed
Long-acting PrEP injection tolerable and acceptable for male volunteers, but dose adjustment needed
Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex
Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine
Monkey studies confirm viability of injectable PrEP drug
Researchers and advocates discuss the microbicides pipeline in Europe
Monthly injectable drug offers 100% protection against HIV in monkeys – could be dosed every three months
